AstraZeneca licenses mAb production tech from Lonza and BioWa

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Cell line, License

AstraZeneca licenses mAb production tech from Lonza and BioWa
AstraZeneca licenses mAb production tech from Lonza and BioWa
AstraZeneca’s biologics division MedImmune has licensed a cell line and antibody production tech from Lonza and BioWa.

The agreement – financial terms of which were not disclosed – enables MedImmune to use the Potelligent CHOK1SV cell line for ‘multiple’ therapeutic antibody drug candidates it is developing.

AstraZeneca’s has been using BioWa’s Potelligent technology – which is used to boost the binding affinity of an antibody by reduce the amount of the sugar fucose present in carbohydrate structure – structure since 2007.

The new agreement adds a Chinese hamster ovary cell line that BioWa and Lonza​ co-developed to the existing deal.

AstraZeneca – through MedImmune - is the second Big Pharma firm to license the antibody production technology this year behind US rival Pfizer, which announced that it will use the system to make candidate biopharmaceutical this summer​.

Like Pfizer, AstraZeneca will use the technology in combination with Lonza's 'Xceed' production system, which is the latest version of the GS manufacturing programme that the Swiss ingredients and life science suppliers firm launched in July last year​.

Lonza spokesman Dominik Werner told BioPharma-Reporter.com that as part of the deal the firm will provide full technical support for cell line development.

He also stressed that: “The Potelligent CHOK1SV cell line retains the desirable features of a high-productivity cell line​,” citing its scalability and the fact in can be used in conjunction with a wide range of bioreactor systems among its advantages.

Werner declined to say whether process and cell development know how gained by Lonza through its work with other licensees would be shared with AstraZeneca under the new agreement.

Related topics: Upstream Processing, Pipelines, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars